Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma and TP53 Mutations in the SYMPATICO Study
(2024) European Hematology Association (EHA) Hybrid Congress — Location: Madrid, Spain (13.June.2024)
Files
DV-011594_Jurczak_EHA2024_SYMPATICOEncorePoster_29May2024.pdf
Open Access - Adobe PDF
- 329.77 KB
Details
- Authors
- Affiliations
Citations
Jurczak, W., Wang, m., Trneny, M., Belada, D., Wrobel, T., Ghosh, N., Keating, M.-M., Van Meerten, T., Fernandez Alvarez, R., von Keudell, G., Thieblemont, ,. C., Peyrade, F., André, M., Hoffmann, M., Naganuma, M., Szafer-Glusman, E., Lin, J., Dean, J. P., Neuenburg, J. K., & Tam, C. (2024). Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma and TP53 Mutations in the SYMPATICO Study. European Hematology Association (EHA) Hybrid Congress, Madrid, Spain. https://hdl.handle.net/2078.5/229594